Pennington, NJ, United States of America

Paul E Morin

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 7.8

ph-index = 9

Forward Citations = 202(Granted Patents)


Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Paul E. Morin

Introduction

Paul E. Morin, based in Pennington, NJ, is a prominent inventor with a remarkable portfolio of 22 patents. His contributions have significantly advanced the fields of biotechnology and therapeutics, particularly in treating diseases associated with fibrosis.

Latest Patents

Among his latest patents are two critical innovations:

1. Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof. This patent presents nucleic acids that encode modified FGF-21 polypeptides, which can express therapeutic proteins essential in treating various fibrosis-related diseases.

2. PD-L1 binding polypeptides for imaging, which includes novel Fn3 domains specifically binding to PD-L1, facilitating the development of imaging agents for diagnostic purposes.

Career Highlights

Paul has worked with several esteemed organizations throughout his career, including Bristol-Myers Squibb Company, where he applied his expertise in drug development and innovative solutions in biomedicine.

Collaborations

Working alongside notable colleagues such as Dasa Lipovsek and Ray Camphausen, Paul E. Morin has fostered collaborations that have enriched the research landscape. These partnerships have played a crucial role in the success of his patent portfolio and the implementation of his groundbreaking ideas.

Conclusion

Paul E. Morin's extensive research and innovative patents exemplify his commitment to advancing medical science. His work continues to pave the way for new therapeutic solutions, showcasing the impactful role of inventors in transforming healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…